Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:03 PM
Ignite Modification Date: 2025-12-25 @ 2:43 PM
NCT ID: NCT04915950
Description: None
Frequency Threshold: 0
Time Frame: Day 1 of dose to maximum of 4 (+/-1) days after last dose (up to maximum of 22 days)
Study: NCT04915950
Study Brief: A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Participants received placebo in the study. 0 None 0 13 6 13 View
Temanogrel 120 mg Participants received temanogrel 120 mg in the study. 0 None 0 13 4 13 View
Temanogrel 60 mg Participants received temanogrel 60 mg in this study. 0 None 0 13 3 13 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Hypoaesthesia NON_SYSTEMATIC_ASSESSMENT Nervous system disorders Medra v24.0 View
Head discomfort NON_SYSTEMATIC_ASSESSMENT Nervous system disorders Medra v24.0 View
Oedema peripheral NON_SYSTEMATIC_ASSESSMENT General disorders Medra v24.0 View
Peripheral swelling NON_SYSTEMATIC_ASSESSMENT General disorders Medra v24.0 View
Dizziness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders Medra v24.0 View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders Medra v24.0 View
Blood creatine phosphokinase increased NON_SYSTEMATIC_ASSESSMENT Investigations Medra v24.0 View
Urinary tract infection NON_SYSTEMATIC_ASSESSMENT Infections and infestations Medra v24.0 View
Hypercholesterolaemia NON_SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders Medra v24.0 View
Arthralgia NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders Medra v24.0 View